Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)

Inclusion Criteria: * Age\> 18 years * Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other validated commercial or public health assay * Documented interstitial pneumonia requiring admission and at least two of the following: 1. Fever ≥ 37.8ºC (tympanic) 2. IL-6 in serum ≥ 25 ng / mL (in the absence of a previous dose of prednisone or equivalent\> 1 mg / kg) or PCR\> 5mg / dL 3. Lymphocytes \<600 mm3 4. Ferritin\> 300 mcg / L that doubles in 24 hours 5. Ferritin\> 600 mcg / L in the first determination and LDH\> 250 U / L 6. D-dimer (\> 1 mg / L) * Informed verbal or administration consent under urgent conditions, documented in the electronic medical record. Exclusion Criteria: * Patients who require mechanical ventilation at the time of inclusion. * AST / ALT values \> 5 folds upper normal limit. * Neutrophil count below 500 cells / mm3 * Platelet count below 50,000 cells / mm3 * Documented sepsis or high suspicion by pathogens other than COVID-19. * Presence of comorbidities that according to clinical judgment could lead to an unfavorable result. * Complicated diverticulitis or intestinal perforation. * Current skin infection (eg, uncontrolled dermopiodermitis). * Immunosuppressive anti-rejection therapy. * Pregnancy or lactation. * Previous treatment with tocilizumab or sarilumab. * Patients participating in some other clinical trial for SARS-CoV-2 infection. * Patients with known hypersensitivity or contraindication to sarilumab or excipients.